The Adrenal Tumour That Makes Hormones: Adrenocortical Carcinoma
Most adrenal nodules are found by accident. A CT ordered for a kidney stone or back pain picks up a lump on top of a kidney, and the report names it. Adrenal incidentalomas show up in around 3% of adults over 50 and up to 10% of people over 80, and adrenocortical adenomas account for 80% to 85% of them (per the 2023 European Society of Endocrinology guideline). Adrenocortical carcinoma sits at the far end of the same list, 0.4% to 4%. What separates the nothing from the rare something is not how the lump looks on one scan. It is mostly hormonal, and it only resolves when the hormone panel, the millimetres and the earlier imaging sit in one line, which is what Healz's memory holds.
This post walks the finding from the top: what the adrenal cortex makes, how these tumors are found, the hormone tests an adrenal mass triggers, the two CT numbers that move the plan, and why the needle stays out while the operation goes first.

What the adrenal cortex actually makes
The adrenal glands sit one on top of each kidney, and the cortex is the outer layer of the gland (NCI). NCI describes the jobs of the hormones it makes in four lines: they balance the water and salt in the body, help keep blood pressure normal, help control the body's use of protein, fat and carbohydrates, and cause the body to have masculine or feminine characteristics.
Those four jobs belong to three hormone families. Aldosterone handles salt and blood pressure. Cortisol handles metabolism and the stress response. Adrenal androgens drive sexual characteristics. A tumor arising in the cortex can keep making any of them, in amounts nobody asked for. A tumor is called functioning when it makes more hormone than normal, and most adrenocortical tumors are functioning (NCI). That is why this disease can announce itself twice, as a shadow on a scan and as a syndrome in a body, and why the two announcements often arrive at different clinics.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
The two routes by which these tumors get found
The first route is hormone excess. Hormone-related symptoms are the main reason for seeking care in approximately 60% of patients with adrenocortical carcinoma, and up to 80% of the tumors turn out to be functioning once biochemical testing is done (NCI). The syndromes that bring people in are Cushing syndrome from cortisol excess, hirsutism and virilization from androgen excess, feminization, precocious puberty in children, and hyperaldosteronism. The second most common presentation is nonspecific abdominal symptoms such as pain or fullness, and a smaller share of cases are found incidentally on imaging ordered for something else (NCI).
The second route is the scan, which is why the base rate matters. Adrenocortical carcinoma is rare: NCI puts the annual incidence at 2 cases per 1 million people, and the ESE/ENSAT guideline estimates 0.7 to 2.0 per million per year in adults, with a median age at diagnosis of 46 (NCI).
The hormonal route is the one that gets fragmented. New diabetes, rising blood pressure, weight gain around the middle, easy bruising, muscle weakness and new facial hair can be filed under five separate headings by five different clinicians. Read as one pattern, those findings are a single question about the adrenal cortex.
The hormone questions an adrenal mass triggers
The workup is not improvised. For any adrenal mass, the 2023 ESE guideline sets a fixed list, and each test answers one question.
- Cortisol. A 1 mg overnight dexamethasone suppression test is recommended to exclude autonomous cortisol secretion. A post-dexamethasone serum cortisol of 50 nmol/L or less (1.8 µg/dL or less) excludes it; anything above that is classed as mild autonomous cortisol secretion. The older 2016 bands of 51 to 138 and above 138 nmol/L are no longer used.
- Catecholamines. Plasma free or urinary fractionated metanephrines are recommended in every patient whose adrenal lesion has features not typical for a benign adenoma.
- Aldosterone. An aldosterone to renin ratio is recommended to evaluate primary aldosteronism in patients with hypertension or unexplained low potassium.
- Sex steroids. When imaging or clinical features raise the possibility of adrenocortical carcinoma, the guideline suggests measuring sex steroids and precursors of steroidogenesis, ideally by tandem mass spectrometry. The ESE/ENSAT carcinoma guideline lists DHEA-S, 17-OH-progesterone, androstenedione, 11-deoxycortisol, testosterone in women, and estradiol in men and postmenopausal women.
The last item is the one most often skipped, and it carries the most information about a cortex that has stopped regulating itself. A single mildly abnormal steroid usually means little. A panel in which several precursors are elevated together is a different signal, and it is only visible when the whole panel is read as a shape rather than value by value. Our companion piece on cortisol and adrenal hormone testing explains what each of those assays measures and why one result is read against the others.
What the scan is measuring, and the numbers that move the plan
Unenhanced CT gives two numbers, and between them they decide most of what follows. The first is density, measured in Hounsfield units, which is effectively a measure of how fatty the tissue is. Benign adenomas are fatty. Carcinomas are not. The second is size.
The 2023 ESE guideline draws the lines explicitly. A homogeneous mass with Hounsfield units of 10 or less is consistent with a benign adrenal mass and needs no further imaging. A mass between 11 and 20 Hounsfield units and under 4 cm falls into a middle band where either immediate additional imaging or a repeat unenhanced CT or MRI at 12 months is suggested. A mass 4 cm or larger with a heterogeneous appearance, or any mass above 20 Hounsfield units, lands in the category where the guideline says that in most cases immediate surgery will be the management of choice. MRI using in-phase and out-of-phase T1-weighted sequences can add specificity to CT, and a chest CT is part of staging because the lungs are a common site of spread (NCI).
Size also carries forward into staging. The AJCC TNM system splits tumors at 5 cm, and the ESE/ENSAT guideline recommends the European Network for the Study of Adrenal Tumours classification, essentially the same system but reserving stage IV for distant metastasis (NCI). Our guide to the workup of an adrenal incidentaloma follows those imaging thresholds through in more detail.
Why the needle stays out and the operation goes first
This part surprises people who expect a biopsy before any cancer treatment. The 2023 ESE guideline recommends against biopsy in the diagnostic workup of adrenal masses unless there is a history of extra-adrenal malignancy. The ESE/ENSAT carcinoma guideline advises against it unless metastatic disease already rules out surgery and the histology is needed to guide drug treatment. The stated reason is plain: differentiating benign from malignant adrenocortical tumors is very challenging on a biopsy only, and biopsy carries a bleeding risk. So the malignancy question is answered on the whole removed tumor, using architectural and nuclear features such as those scored in the Weiss system, not on a core of tissue.
Before any operation, a pheochromocytoma must be excluded (ESE/ENSAT), which is what the metanephrines are for. A pheochromocytoma arises in the adrenal medulla, the inner part of the same gland, and makes catecholamines. Operating on one that nobody knew about is a materially different and more dangerous procedure, so the test comes before the operation is booked.
The operation itself is specific. The ESE/ENSAT guideline recommends complete en bloc resection of all adrenal tumors suspected to be adrenocortical carcinoma, including the peritumoral and periadrenal retroperitoneal fat, and advises against enucleation or partial adrenal resection. Intraoperative tumor rupture or spillage, and incomplete resection, are associated with very high recurrence rates. NCI puts it directly: radical open surgical excision is the treatment of choice for localized disease and remains the only method for achieving long-term disease-free survival.
Mitotane is the drug specific to this cancer. It is adrenolytic, meaning it acts on adrenal cortex tissue. After a complete resection, the ESE/ENSAT guideline recommends adjuvant mitotane for patients with no macroscopic residual tumor who have a perceived high risk of recurrence, started as soon as clinically possible and continued for at least 2 years but no longer than 5. NCI notes that in the adjuvant setting it has shown some progression-free or disease-free survival advantage without an overall survival advantage, and that in unresectable disease it produces responses in about 20% to 30% of patients with measurable disease, with gastrointestinal and neurological toxicity often limiting prolonged use.
How Healz reads a hormone panel against the scan
A hormone panel on its own is a column of numbers with a few flags. The same panel read next to the nodule's size, its density in Hounsfield units and the scan from two years ago is a different object: it answers whether anything is moving. Healz is equipped with memory, so the cortisol result, the metanephrines, the aldosterone and renin, and the millimetre measurement in each radiology report are pulled out of what you upload, dated, and kept in one line. Abnormal values stay up front. Last year's measurement sits beside this year's instead of in a different portal.
The rest of the case lives in the same chat, not ten apps and three logins. Frontier AI works the whole file, so an AI CT scan analysis of the radiology wording is read beside the hormone results, not weeks after them, and as an AI lab report reader Healz takes the panel as a shape instead of a list. Healz is equipped with root-cause technology, which is why it does not stop at the words adrenal nodule: it asks the hormone questions a rushed visit skips, cross-checks the case against more than a million rare cases, and searches the current studies and trials for what the pattern fits. You can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- Is an adrenal nodule found on a CT scan usually cancer?
Usually not. Adrenocortical adenomas and bilateral adrenal hyperplasia make up 80% to 85% of adrenal incidentalomas, while adrenocortical carcinoma accounts for 0.4% to 4% (ESE 2023). The carcinoma itself is rare, at roughly 2 cases per 1 million people a year (NCI), so a nodule is a reason for a defined workup, not a reason to assume the worst.
- What hormone tests are done for an adrenal mass?
The 2023 ESE guideline sets out a 1 mg overnight dexamethasone suppression test for cortisol, plasma free or urinary fractionated metanephrines when the lesion is not typical of a benign adenoma, and an aldosterone to renin ratio when there is hypertension or unexplained low potassium. When carcinoma is suspected, sex steroids and steroid precursors are added, ideally by mass spectrometry.
- Does a 4 cm adrenal tumor need surgery?
Size alone does not decide it, but it moves the category. The ESE guideline treats a mass of 4 cm or more with a heterogeneous appearance, or any mass above 20 Hounsfield units, as the group where immediate surgery is in most cases the management of choice.
- Why is an adrenal tumor not biopsied before surgery?
Because a biopsy often cannot answer the question. The ESE/ENSAT guideline states that differentiating benign from malignant adrenocortical tumors is very challenging on a biopsy only, and biopsy carries a bleeding risk, so it is advised against unless there is a history of cancer elsewhere or metastatic disease has already ruled out an operation. The diagnosis is made on the whole resected tumor.
An adrenal nodule on a scan is almost always a footnote, and in the small number of cases where it is not, the tell is hormonal rather than visual. What makes that call reliable is holding the hormone panel, the millimetres and the previous scan in one place and reading them against each other, which is the whole job of memory that actually remembers.
Written by Healz Team · Filed under Health Insights